九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300705 九典制药

已收盘 11-26 15:00:00

{"stockData":{"symbol":"300705","market":"SZ","secType":"STK","nameCN":"九典制药","latestPrice":23.8,"timestamp":1732604619000,"preClose":23.3,"halted":0,"volume":5923834,"delay":0,"floatShares":365000000,"shares":494000000,"eps":1.0276,"marketStatus":"已收盘","marketStatusCode":5,"change":0.5,"latestTime":"11-26 15:00:00","open":23.22,"high":24.46,"low":23.21,"amount":143000000,"amplitude":0.0536,"askPrice":23.81,"askSize":15,"bidPrice":23.8,"bidSize":88,"shortable":0,"etf":0,"ttmEps":1.0276,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732671000000},"adr":0,"adjPreClose":23.3,"symbolType":"stock","openAndCloseTimeList":[[1732584600000,1732591800000],[1732597200000,1732604400000]],"highLimit":25.63,"lowLimit":20.97,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":494383899,"pbRate":4.98,"roa":"--","roe":"20.46%","epsLYR":1.07,"committee":0.74359,"marketValue":11766000000,"floatMarketCap":8686000000,"peRate":23.160762,"changeRate":0.0215,"turnoverRate":0.0162,"status":0},"requestUrl":"/m/hq/s/300705","defaultTab":"news","newsList":[{"id":"2486707073","title":"九典制药：博时基金、前海开源基金等多家机构于11月26日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2486707073","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486707073?lang=zh_cn&edition=full","pubTime":"2024-11-26 19:14","pubTimestamp":1732619667,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月26日九典制药发布公告称博时基金、前海开源基金、西部证券、华福证券、永赢基金、平安证券、汇添富基金、招商基金、华源证券、安信基金于2024年11月26日调研我司。第三季度公司贴膏剂销售总额为 4.62 亿元，同比增长15.57%，销售数量同比增长 80.13%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112600032890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2486908133","title":"九典制药（300705）股东朱志宏质押130万股，占总股本0.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486908133","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486908133?lang=zh_cn&edition=full","pubTime":"2024-11-25 21:22","pubTimestamp":1732540963,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药11月25日公开信息显示，股东朱志宏向国泰君安证券股份有限公司合计质押130.0万股，占总股本0.26%。质押详情见下表：截止本公告日，股东朱志宏已累计质押股份650.0万股，占其持股总数的3.95%。九典制药主营业务：医药产品的研发、生产和销售。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500031195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2485722233","title":"11月22日九典制药跌6.38%，华安聚优精选混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485722233","media":"证券之星","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485722233?lang=zh_cn&edition=full","pubTime":"2024-11-22 16:32","pubTimestamp":1732264354,"startTime":"0","endTime":"0","summary":"证券之星消息，11月22日九典制药跌6.38%，收盘报23.19元，换手率1.82%，成交量6.62万手，成交额1.58亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共60家，其中持有数量最多的公募基金为华安聚优精选混合。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112200026183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2484991846","title":"11月19日九典制药涨5.90%，华安聚优精选混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484991846","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484991846?lang=zh_cn&edition=full","pubTime":"2024-11-19 16:17","pubTimestamp":1732004270,"startTime":"0","endTime":"0","summary":"证券之星消息，11月19日九典制药涨5.90%，收盘报24.23元，换手率1.74%，成交量6.36万手，成交额1.5亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共60家，其中持有数量最多的公募基金为华安聚优精选混合。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900025325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2484991338","title":"九典制药涨5.90%，首创证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2484991338","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484991338?lang=zh_cn&edition=full","pubTime":"2024-11-19 16:17","pubTimestamp":1732004264,"startTime":"0","endTime":"0","summary":"今日九典制药（300705）涨5.90%，收盘报24.23元。2024年8月27日，首创证券研究员王斌发布了对九典制药的研报《公司简评报告：盈利能力持续提升，产品梯队日益完善》，该研报对九典制药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为89.3%。此外，华安证券研究员谭国超,李昌幸，中泰证券研究员祝嘉琦,孙宇瑶近期也对该股发布了研报，同样给出“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为开源证券的蔡明子。九典制药（300705）个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900025321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","601136"],"gpt_icon":0},{"id":"2484999351","title":"九典制药（300705）11月19日主力资金净买入660.83万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484999351","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484999351?lang=zh_cn&edition=full","pubTime":"2024-11-19 15:24","pubTimestamp":1732001069,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月19日收盘，九典制药报收于24.23元，上涨5.9%，换手率1.74%，成交量6.36万手，成交额1.5亿元。11月19日的资金流向数据方面，主力资金净流入660.83万元，占总成交额4.39%，游资资金净流入83.65万元，占总成交额0.56%，散户资金净流出744.48万元，占总成交额4.95%。九典制药主营业务：医药产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111900019235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2484666469","title":"九典制药：平安养老、东吴证券等多家机构于11月15日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2484666469","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484666469?lang=zh_cn&edition=full","pubTime":"2024-11-18 09:03","pubTimestamp":1731891810,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月15日九典制药发布公告称平安养老、东吴证券、申万菱信基金、汇丰晋信基金于2024年11月15日调研我司。第三季度贴膏剂院外实现销售收入 0.58亿元，同比增长 113.49%。此外，多款仿制药有望参加首轮国家集采，为公司未来利润增长提供支撑。该股最近90天内共有16家机构给出评级，买入评级13家，增持评级3家；过去90天内机构目标均价为29.0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800001452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0009","300705","BK0239","601555","BK0188","BK0028","BK0183","BK0276","BK0012"],"gpt_icon":0},{"id":"2484663349","title":"【机构调研记录】申万菱信基金调研盛美上海、九典制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2484663349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484663349?lang=zh_cn&edition=full","pubTime":"2024-11-18 08:02","pubTimestamp":1731888139,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月15日披露的机构调研信息，申万菱信基金近期对2家上市公司进行了调研，相关名单如下：1）盛美上海 个股亮点：公司主要从事高端半导体设备的研发、生产和销售。2）九典制药 个股亮点：九典转02于2023-10-13上市申万菱信基金成立于2004年，截至目前，资产管理规模906.03亿元，排名64/208；资产管理规模791.33亿元，排名55/208；管理公募基金数144只，排名48/208；旗下公募基金经理27人，排名47/208。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800001144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688082","BK0251","300705","BK0239"],"gpt_icon":0},{"id":"2482311445","title":"华源证券：给予九典制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2482311445","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482311445?lang=zh_cn&edition=full","pubTime":"2024-11-09 17:55","pubTimestamp":1731146119,"startTime":"0","endTime":"0","summary":"华源证券股份有限公司刘闯近期对九典制药进行研究并发布了研究报告《24Q3业绩超预期，持续打造外用贴膏产品矩阵》，本报告对九典制药给出买入评级，当前股价为24.7元。考虑到公司是国内领先的贴膏龙头企业，产品组合不断扩充，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有16家机构给出评级，买入评级13家，增持评级3家；过去90天内机构目标均价为29.0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110900007401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","161027"],"gpt_icon":0},{"id":"2481147324","title":"九典制药：天风证券、宏道投资等多家机构于11月8日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2481147324","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481147324?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:48","pubTimestamp":1731055713,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月8日九典制药发布公告称天风证券、宏道投资于2024年11月8日调研我司。第三季度公司贴膏剂销售总额为 4.62 亿元，同比增长15.57%，销售数量同比增长 80.13%。其中院内收入同比增长8.47%，销售数量同比增长 73.02%；院外收入同比增长113.49%，销售数量同比增长 143.74%。此外，多款仿制药有望参加首轮国家集采，为公司未来利润增长提供支撑。该股最近90天内共有16家机构给出评级，买入评级13家，增持评级3家；过去90天内机构目标均价为29.0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800027252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0276","300705","601162"],"gpt_icon":0},{"id":"2481141897","title":"11月8日九典制药涨5.42%，华安聚优精选混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481141897","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481141897?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:13","pubTimestamp":1731053609,"startTime":"0","endTime":"0","summary":"证券之星消息，11月8日九典制药涨5.42%，收盘报24.7元，换手率4.27%，成交量15.36万手，成交额3.79亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共60家，其中持有数量最多的公募基金为华安聚优精选混合。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800025770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2481418901","title":"九典制药涨5.42%，首创证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481418901","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481418901?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:13","pubTimestamp":1731053598,"startTime":"0","endTime":"0","summary":"今日九典制药（300705）涨5.42%，收盘报24.7元。2024年8月27日，首创证券研究员王斌发布了对九典制药的研报《公司简评报告：盈利能力持续提升，产品梯队日益完善》，该研报对九典制药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为89.3%。此外，华安证券研究员谭国超,李昌幸，中泰证券研究员祝嘉琦,孙宇瑶近期也对该股发布了研报，同样给出“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为开源证券的蔡明子。九典制药（300705）个股概况：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110800025766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601136","300705"],"gpt_icon":0},{"id":"2481481902","title":"九典制药（300705）股东朱志宏质押520万股，占总股本1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481481902","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481481902?lang=zh_cn&edition=full","pubTime":"2024-11-07 21:20","pubTimestamp":1730985634,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药11月7日公开信息显示，股东朱志宏向国泰君安证券股份有限公司合计质押520.0万股，占总股本1.06%。质押详情见下表：截止本公告日，股东朱志宏已累计质押股份520.0万股，占其持股总数的3.16%。九典制药主营业务：医药产品的研发、生产和销售。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110700035523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2481519699","title":"华福证券：给予九典制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2481519699","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481519699?lang=zh_cn&edition=full","pubTime":"2024-11-05 11:56","pubTimestamp":1730779018,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司陈铁林近期对九典制药进行研究并发布了研究报告《业绩超预期，贴膏赛道壁垒坚固，长期成长动力充沛》，本报告对九典制药给出买入评级，当前股价为22.94元。　　公司持续加强对终端渠道掌控能力，持续降低销售费用率。最新盈利预测明细如下：该股最近90天内共有16家机构给出评级，买入评级13家，增持评级3家；过去90天内机构目标均价为29.0。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500017441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","161027"],"gpt_icon":0},{"id":"2480230437","title":"九典制药(300705.SZ)股东段立新拟减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2480230437","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480230437?lang=zh_cn&edition=full","pubTime":"2024-11-04 20:15","pubTimestamp":1730722554,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九典制药(300705.SZ)发布公告，持股12.30%的股东段立新女士，计划在公告披露日起15个交易日后的3个月内以集中竞价交易或大宗交易方式减持公司股份不超过1477.22万股(占公司总股本比例3%)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2480304812","title":"九典制药最新公告：股东计划减持公司股份不超过3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480304812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480304812?lang=zh_cn&edition=full","pubTime":"2024-11-04 20:09","pubTimestamp":1730722178,"startTime":"0","endTime":"0","summary":"九典制药公告，公司持股5%以上股东段立新计划在本公告披露日起15个交易日后的3个月内，以集中竞价交易或大宗交易方式减持公司股份不超过14,772,180股，占公司总股本比例的3%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400028595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2480361556","title":"华安证券：给予九典制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480361556","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480361556?lang=zh_cn&edition=full","pubTime":"2024-11-03 21:48","pubTimestamp":1730641691,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超,李昌幸近期对九典制药进行研究并发布了研究报告《盈利能力稳步提升，24Q3利润端表现亮眼》，本报告对九典制药给出买入评级，当前股价为23.47元。九典制药(30070 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20241103/c663123791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["600909","300705"],"gpt_icon":0},{"id":"2480998841","title":"九典制药：有知名机构盘京投资参与的多家机构于10月31日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2480998841","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480998841?lang=zh_cn&edition=full","pubTime":"2024-11-02 17:31","pubTimestamp":1730539883,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年11月1日九典制药发布公告称盘京投资、中泰证券、杉树资产于2024年10月31日调研我司。该股最近90天内共有15家机构给出评级，买入评级12家，增持评级3家；过去90天内机构目标均价为29.0。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110200006956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2480275800","title":"九典制药（300705）11月1日主力资金净买入850.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480275800","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480275800?lang=zh_cn&edition=full","pubTime":"2024-11-01 15:21","pubTimestamp":1730445703,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月1日收盘，九典制药报收于23.47元，上涨0.95%，换手率2.48%，成交量8.94万手，成交额2.12亿元。11月1日的资金流向数据方面，主力资金净流入850.33万元，占总成交额4.01%，游资资金净流出1357.69万元，占总成交额6.41%，散户资金净流入507.36万元，占总成交额2.39%。九典制药主营业务：医药产品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100022692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2479281552","title":"九典制药（300705）10月30日主力资金净卖出633.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479281552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479281552?lang=zh_cn&edition=full","pubTime":"2024-10-30 15:24","pubTimestamp":1730273087,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月30日收盘，九典制药报收于24.0元，下跌3.77%，换手率3.11%，成交量11.2万手，成交额2.7亿元。10月30日的资金流向数据方面，主力资金净流出633.34万元，占总成交额2.34%，游资资金净流出113.16万元，占总成交额0.42%，散户资金净流入746.5万元，占总成交额2.76%。九典制药主营业务：医药产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000022026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-10-10","address":"湖南省长沙市浏阳市经济技术开发区健康大道1号","stockEarnings":[{"period":"1week","weight":-0.0177},{"period":"1month","weight":-0.0071},{"period":"3month","weight":0.1059},{"period":"6month","weight":-0.0634},{"period":"1year","weight":0.1654},{"period":"ytd","weight":0.0118}],"companyName":"湖南九典制药股份有限公司","boardCode":"AI0027","perCapita":"31149股","boardName":"医药制造业","registeredCapital":"49438万元","compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0121},{"period":"3month","weight":0.1488},{"period":"6month","weight":0.0544},{"period":"1year","weight":0.0752},{"period":"ytd","weight":0.0957}],"survey":"　　湖南九典制药股份有限公司主营业务为医药产品的研发、生产和销售，产品主要包括药品制剂、原料药、药用辅料及CXO服务四大类别。公司是国家企业技术中心、国家高技术产业化示范工程企业、国家火炬计划重点高新技术企业、湖南省高新技术企业。公司设有药物研究院，其被认定为湖南省企业技术中心，公司建有博士后科研工作站、新型凝胶膏剂湖南省工程研究中心、湖南省呼吸道药物工程技术研究中心等创新平台。","serverTime":1732643275935,"listedPrice":10.37,"stockholders":"11716人(较上一季度增加23.57%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九典制药,300705,九典制药股票,九典制药股票老虎,九典制药股票老虎国际,九典制药行情,九典制药股票行情,九典制药股价,九典制药股市,九典制药股票价格,九典制药股票交易,九典制药股票购买,九典制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}